Abstract: The present invention is directed to a novel method for measurement of glycated hemoglobin, as well as assay methods and processes that can be used outside the medical laboratory setting to determine the fraction of total hemoglobin that is glycated.

Abstract: The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

Abstract: The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin,, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

Abstract: The present invention is directed to the prevention in vivo of the nonenzymatic glycation of albumin, which generates biologically active Amadori glucose adducts in the albumin molecule, as well as methods of using compounds that protect against nonenzymatic glycation in vivo to treat kidney dysfunction.

Abstract: The present invention is directed to the prevention in vivo of post-secretory Amadori modifications in the Apo B molecule, as well as methods of using compounds that protect against these modifications in vivo to treat hypercholesterolemia and vascular dysfunction.

Abstract: This invention deals with genetically engineered immunoglobulins with affinity and specificity for (human) glycated albumin. The invention is directed to the DNA which encodes the immunoglobulins. The DNA sequence can be manipulated to produce chimeras and fragments such as Fab, F(ab').sub.2 or ScFv. The immunoglobulins can be produced by recombinant DNA methods and readily purified. The invention also provides a novel and improved method for treating the complications of diabetes.

Abstract: Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposited at sites of diabetic tissue damage. Glycated albumin inhibits the growth of cells. Treatment with monoclonal anti-glycated albumin antibody reverses the growth inhibition caused by glycated albumin. In addition, glycated albumin stimulates the production of type IV collagen by kidney cells. Antibodies which bind to glycated albumin prevent the stimulation of type IV collagen production.

Abstract: An antibody specifically immunoreactive with glycated LDL and methods for using the antibody are provided. The antibody can be used for quantitating amounts of glycated LDL in a sample, for monitoring glycemic control in diabetic patients, for diagnosing disease, for monitoring and diagnosing atherosclerotic cardiovascular disease, and for inhibiting accumulation of LDL cholesterol by cells in tissues subject to atherosclerotic disease.

Abstract: A method of isolating soluble pancreatic islet antigen employs extraction with a non-ionic detergent and fractionation on a gel filtration column. Fractions are screened for high immunoreactivity with diabetic serum which is positive for ICA immunofluorescence when tested on tissue sections of a pancreas from a human blood group O donor. The isolated soluble antigen is suitable for measuring autoantibodies in both complement fixation assays as well as ELISA-type and immunoblotting formats. Methods of using isolated soluble antigen to test serum for autoantibodies are also taught.

Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with glycated albumin and insignificantly reactive with other proteins, as well methods of using these monoclonal antibodies to detect glycated albumin.

Abstract: Monoclonal antibodies specific for an epitope found on hemoglobin glycated both in vivo and in vitro but not found on hemoglobin A.sub.o or hemoglobin A.sub.1c are provided. Use of these antibodies to measure glycohemoglobin levels in the blood provides a measure of the glucose levels in the erythrocyte for the previous 90-120 days. No reduction of the blood sample is required to produce the epitope recognized by the monoclonal antibodies.

Abstract: An analytical reader device having an elongated fixed standard tray supporting thereon a strip of standard wells and an elongated movable sample tray supporting thereon a strip of sample wells. A track arrangement connects and allows the movable sample tray to slide along the fixed standard tray. A rack gear is secured along the side of the movable sample tray opposite to the track arrangement. A geared dial is rotatably supported on a support plate secured to the fixed standard tray. The teeth of the geared dial mesh with the teeth of the rack gear so that as the movable sample tray slides the dial rotates. When a sample well is positioned adjacent the visually similar standard well, the dial is turned so that the correct concentration reading thereon appears through a fixed readout window.